Abstract:CCR2 is predominantly expressed by monocytes/macrophages with strong proinflammatory functions, prompting the development of CCR2 antagonists to dampen unwanted immune responses in inflammatory and autoimmune diseases. Paradoxically, CCR2-expressing monocytes/macrophages, particularly in tumor microenvironments, can be strongly immunosuppressive. Thus, targeting the recruitment of immunosuppressive monocytes/macrophages to tumors by CCR2 antagonism has recently been investigated as a strategy to modify the tumor microenvironment and enhance anti-tumor immunity. We present here that beneficial effects of CCR2 antagonism in the tumor setting extend beyond blocking chemotaxis of suppressive myeloid cells. Signaling within the CCL2/CCR2 axis shows underappreciated effects on myeloid cell survival and function polarization. Apart from myeloid cells, T cells are also known to express CCR2. Nevertheless, tissue homing of Treg cells among T cell populations is preferentially affected by CCR2 deficiency. Further, CCR2 signaling also directly enhances Treg functional potency. Thus, although Tregs are not the sole type of T cells expressing CCR2, the net outcome of CCR2 antagonism in T cells favors the anti-tumor arm of immune responses. Finally, the CCL2/CCR2 axis directly contributes to survival/growth and invasion/metastasis of many types of tumors bearing CCR2. Together, CCR2 links to two main types of suppressive immune cells by multiple mechanisms. Such a CCR2-assoicated immunosuppressive network is further entangled with paracrine and autocrine CCR2 signaling of tumor cells. Strategies to target CCL2/CCR2 axis as cancer therapy in the view of three types of CCR2-expessing cells in tumor microenvironment are discussed.

Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead

CXC Chemokine Receptors in the Tumor Microenvironment and an Update of Antagonist Development

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target

Potential Roles and Targeted Therapy of the CXCLs/CXCR2 Axis in Cancer and Inflammatory Diseases

Insights on CXC Chemokine Receptor 2 in Breast Cancer: an Emerging Target for Oncotherapy.

CXCR6-based Immunotherapy in Autoimmune, Cancer and Inflammatory Infliction

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

Chemokine Systems in Oncology: from Microenvironment Modulation to Nanocarrier Innovations.

Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers

Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

Targeting TNFR2 for cancer immunotherapy: recent advances and future directions

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy